Prognostic Factors in Head and Neck Non-Hodgkin's Lymphoma with Special Reference to Serum Lactic Dehydrogenase and Serum Copper

Hisamitsu, Shigemasa; Shibuya, Hitoshi; Hoshina, Masao; Horiuchi, Jun‐ichi

doi:10.3109/02841869009096383

Cited by 4 publications

(2 citation statements)

References 23 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, we observed that patients that had DLBCL recurrence within 18 months presented elevated LDH levels at diagnosis (8 out of 14; 57.14%) (data not shown). Together, our results corroborate the literature findings concerning an association between high LDH levels and worse prognosis (Chi et al, 2012; Gordon et al, 1995; Hisamitsu et al, 1990).…”

Section: Discussionsupporting

confidence: 92%

“…Although LDH is a non-specific marker for lymphomas, its levels reflect tumor burden, the reason why it has been consistently used in clinical practice as a prognostic biomarker for NHL (Agung et al, 2019;Ferraris et al, 1979;Pfreundschuh, 2004). In a retrospective analysis, Chi et al (2012) (Chi et al, 2012;Gordon et al, 1995;Hisamitsu et al, 1990).…”

Section: Ta B L E 2 Correlation Between Gender and Clinical-pathologi...mentioning

confidence: 99%

See 1 more Smart Citation

Primary diffuse large B‐cell lymphoma of the head and neck in a Brazilian single‐center study

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Ta B L E 2 Correlation Between Gender and Clinical-pathologi...mentioning

confidence: 99%

Primary diffuse large B‐cell lymphoma of the head and neck in a Brazilian single‐center study

et al. 2022

View full text Add to dashboard Cite

show abstract

Diagnosis of endometrial cancer in patients with postmenopausal bleeding by analysis of the lactate dehydrogenase isoenzyme activity profile in uterine fluid

Niklasson

Skude²,

Maršál

et al. 2004

Gynecologic Oncology

View full text Add to dashboard Cite

Beta 2 Microglobulin Level as an Indicator of Prognosis in Diffuse Large Cell Lymphoma

Avilés¹,

Zepeda²,

Díaz-Maqueo³

et al. 1992

Leukemia & Lymphoma

View full text Add to dashboard Cite

We report results of our investigation of prognostic factors for patients with diffuse large cell lymphoma (DLCL) who were entered on the same treatment protocol and who had known pretreatment serum beta 2 microglobulin levels. Serum beta 2 microglobulin, bone marrow involvement, performance status and lactic dehydrogenase (LDH) levels were associated with a poor prognosis in univariate analysis. However, only beta 2 microglobulin remained of prognostic significance in a multivariate analysis with statistical differences at different cut off levels. We believe that beta 2 microglobulin levels accurately separate patients into low-, intermediate- and high-risk patients. It is concluded that serum beta 2 microglobulin is the most significant prognostic factor currently available for DLCL and should be incorporated in the initial staging in order to provide a basis for designing the therapeutic approach in these cases.

show abstract

Prognostic Factors in Head and Neck Non-Hodgkin's Lymphoma with Special Reference to Serum Lactic Dehydrogenase and Serum Copper

Cited by 4 publications

References 23 publications

Primary diffuse large B‐cell lymphoma of the head and neck in a Brazilian single‐center study

Primary diffuse large B‐cell lymphoma of the head and neck in a Brazilian single‐center study

Diagnosis of endometrial cancer in patients with postmenopausal bleeding by analysis of the lactate dehydrogenase isoenzyme activity profile in uterine fluid

Beta 2 Microglobulin Level as an Indicator of Prognosis in Diffuse Large Cell Lymphoma

Contact Info

Product

Resources

About